Kadmon (KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What other stocks do shareholders of Kadmon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kadmon investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Organigram (OGI) , KushCo (KSHB) , Zosano Pharma (ZSAN) and Bionano Genomics (BNGO) .

NYSE:KDMN

Kadmon (KDMN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $9.50
▼
$9.50
50-Day Range: $9.50
▼
$9.50
52-Week Range: $3.19
▼
$9.50

Volume: 1,052 shs
Average Volume: 5.11 million shs
Market Capitalization: $1.70 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Kadmon alerts:

Ad Weiss Ratings

Nvidia’s Quiet $1 Trillion Pivot

Nvidia recently added $277 billion in market cap … IN ONE DAY.

Find out details on these three critical Nvidia partners immediately.

About Kadmon Stock (NYSE:KDMN)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Ad Weiss Ratings

Nvidia’s Quiet $1 Trillion Pivot

Nvidia recently added $277 billion in market cap … IN ONE DAY.

Find out details on these three critical Nvidia partners immediately.

KDMN Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive KDMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Sub-Industry: N/A
Current Symbol: NYSE:KDMN
CUSIP: N/A
CIK: N/A
Web: N/A
Phone: 12123086000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 178,521,000
Free Float: N/A
Market Cap: $1.70 billion
Optionable: Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Competitors

View All Competitors

KDMN Stock Analysis - Frequently Asked Questions

When did Kadmon IPO?: Kadmon (KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
What other stocks do shareholders of Kadmon own?: Based on aggregate information from My MarketBeat watchlists, some other companies that Kadmon investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Organigram (OGI), KushCo (KSHB), Zosano Pharma (ZSAN) and Bionano Genomics (BNGO).